When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

After decades of discovery, inherited variations have been identified in approximately 20
genes that affect about 80 medications and are actionable in the clinic. And some …

Clinical annotations are one of the most popular resources available on the
Pharmacogenomics Knowledgebase (PharmGKB). Each clinical annotation summarizes the …

Knowledge gained from observational cohort studies has dramatically advanced the
prevention and treatment of diseases. Many of these cohorts, however, are small, lack …

The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …

This document is an update to the 2011 Clinical Pharmacogenetics Implementation
Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Purpose: Owing to its highly polymorphic nature and major contribution to the metabolism
and bioactivation of numerous clinically used drugs, CYP2D6 is one of the most extensively …

Classical genetic approaches for interpreting variants, such as case-control or co-
segregation studies, require finding many individuals with each variant. Because the …

The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly
polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism …